AHA 2022 Highlights Podcast

In this episode (19.08 minutes), Medicom’s correspondent covers 6 presentations from the Annual Meeting of the American Heart Association (AHA 2022), held in Chicago (IL, US) from 5-7 November 2022.
The topics discussed are:

1. Torsemide not superior to furosemide in hospitalized HF patients
   Comparing treatment with loop diuretics furosemide and torsemide in hospitalised patients with heart failure (HF) did not ascertain an advantage in the clinical outcome of all-cause mortality in the phase 3 TRANSFORM-HF trial. Furthermore, no difference was found in total hospitalisations at 12 months.
2. Empagliflozin beneficial for kidney disease progression and CV outcomes
   Empagliflozin significantly reduced the risk of the composite outcome of progression of kidney disease or death from cardiovascular (CV) causes by 28% in the phase 3 EMPA-KIDNEY trial. The results also showed a 14% decrease in hospitalisation due to any cause.
3. Olpasiran leads to dramatic reductions in Lp(a) concentrations
   Olpasiran, a small interfering RNA molecule, successfully reduced lipoprotein levels by >90% in patients with atherosclerotic cardiovascular disease in the phase 2 OCEAN(a)-DOSE trial. The agent was well tolerated with only mild increases in injection site reactions.
4. Grafting with radial artery: an underrated option in CABG surgery?
   Coronary artery bypass graft (CABG) procedures using the radial artery as a conduit for the second most important target vessel had superior clinical outcomes after 15 years. Compared with the free right internal thoracic artery (RITA) and a saphenous vein graft (SVG), the use of the radial artery entailed a 26% and a 29% reduction, respectively, in major adverse cardiac events (MACE).
5. Dietary supplements futile in lowering LDL-C
   Rosuvastatin at a low dose clearly outperformed placebo and various dietary supplements in decreasing LDL-cholesterol (LDL-C), total cholesterol and triglycerides. Furthermore, no supplement was superior to placebo in lowering LDL-C.
6. The endothelin system: a new target for resistant high blood pressure
   Two different doses of aprocitentan were superior to placebo in patients with insufficiently treated hypertension despite intensive therapy. After 4 weeks, the systolic BP was significantly more decreased and this effect was maintained during the open label study part of 32 weeks.

Enjoy listening!

Copyright ©2022 Medicom Medical Publishers



Posted on 28 November 202227 June 2024